Sanofi, Glaxo covid vaccine works well in mid-stage study, shot on track

Sanofi and GlaxoSmithKline Plc reported positive results from a redo of a mid-stage study for their Covid-19 vaccine, putting the delayed shot on track for possible clearance by the end of the year.

Volunteers showed a similar antibody response to people who have recovered from the coronavirus, the companies said in a statement Monday. Those with evidence of a prior infection had a particularly high immune response after a single dose, suggesting the shot could be a good booster candidate.

The results come as a relief for the two partners, two of the biggest and most experienced companies in the